bullish

IN8bio

INAB: Introducing INB-600, A ?d T Cell Engager Platform

154 Views17 Mar 2025 14:00
Issuer-paid
IN8bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors. Its pipeline is built...
What is covered in the Full Insight:
  • Introduction to IN8bio and DeltEx Platform
  • Financial and Operational Results for 2024
  • Details on INB-100 and Complete Remission in AML
  • Introduction of INB-600 γδ T Cell Engager Platform
  • Future Outlook and Cash Position
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 15-minute read)
Related Insights
More »
    Loading
Trending Collections
More »
    Loading
Trending Insights
More »
    Loading
Top Unpaywalled Insights
More »
    Loading
Discussions
(Paid Plans Only)
chart-bar
Logo
Zacks Small Cap Research
Research Coverage on Small and Micro-Cap Companies
Zacks Small Cap Research
Equity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x